Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation. 0

Automated summary

In this study, 65 individuals opted to receive fluvoxamine for COVID-19 treatment, with a 0% hospitalization rate and 0% residual symptoms. In comparison, 48 individuals who chose observation alone had a hospitalization rate of 12.5% and residual symptoms in 60% of cases. This suggests that fluvoxamine may help alleviate the severity and duration of COVID-19.